Meeting
2021 ASCO Annual Meeting
An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).
Presenter
Mariam Jamal-Hanjani, MRCP, PhD, BSc, MRCP, PhD
University College London
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04032847
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9138)
DOI
10.1200/JCO.2021.39.15_suppl.TPS9138
Abstract #
TPS9138
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Lorlatinib in TKI naïve, advanced ROS1-positive non-small-cell lung cancer: A multicenter, open-label, single-arm, phase 2 trial.
Speaker: Beung Chul . AHN, MD
Videos & Slides
2024 ASCO Annual Meeting
Efficacy and safety of erdafitinib in adults with NSCLC and prespecified fibroblast growth factor receptor alterations in the phase 2 open-label, single-arm RAGNAR trial.
Speaker: Martin H. Schuler, MD
Videos & Slides
2023 ASCO Annual Meeting
Efficacy and safety of tunlametinib in patients with advanced NRAS-mutant melanoma: A multicenter, open-label, single-arm, phase 2 study.
Speaker: Lu Si, MD
Speaker: Panel Discussion